Grand Pharmaceutical's (HKG:0512) phase 2 clinical trial of its STC3141 drug for sepsis in China achieved clinical endpoints, according to a Tuesday filing with the Hong Kong bourse.
The results confirmed the effectiveness and safety of STC3141 in the treatment of sepsis, showing the drug achieved a lower sequential organ failure assessment score compared with the baseline.
The first treatment program centered on rebuilding immune homeostasis worldwide, the filing said.
The trial, conducted by Grand Pharma's Australian subsidiary Grand Medical, enrolled 180 patients, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.